Diabetic macular edema and vision loss anti-VEGF therapy

16^th International Conference on Biosimilars and Pharmaceuticals & 3^rd Worldwide Forum on Alzheimer and Dementia12^th International Conference on Epidemiology & Public Health

June 23-24, 2023 | Paris, France

Marija Brajovic

Hipm Montefarm Institution, Montenegro

Keynote: J Biomed Pharm Sci

Abstract :

Diabetic retinopathy is one of the most serious consequences of diabetes and is the leading cause of vision loss in the world vascular endothelial growth factor (VEGF) is a key driver of vascular leakage in DME. An anti-VEGF therapy as a standard must be carefully monitored. The effectiveness and safety of this therapy was examined by randomized and masked inferiority trials on patients and it was determined that the frequency of application of this therapy does not affect the quality of treatment. Received every 12-16 weeks, these drugs gave the same results as when they were applied for 4 weeks. A significant improvement in visual acuity, good tolerability and cessation or reduction of unexpected reactions during the period of application every 12-16 weeks was observed. The most frequently reported side effect included mild bleeding from the conjunctiva.

Biography :

Marina Brajovic was graduated at Faculty of Management in Bar also Secondary Medical School-pharmaceutical technician and she is having an experience pharmaceutical technician at public pharmacies at 2001-2021; now in 2021 her current position is commercialist at Commercial Sector for OTC drugs.